Key Highlights
- $100 million Series C funding led by Khosla Ventures, 5AM Ventures, and others.
- Funds to expand the Karius Test® beyond 400 U.S. hospitals, aiming for broader healthcare access.
- New board members include high-profile figures from Khosla Ventures, Gilde Healthcare, and more.
Source: Business Wire
Notable Quotes
- “Every minute in the U.S., five cancer patients are admitted to the hospital due to infections… This worrying reality emphasizes a critical gap in our healthcare system: the urgent need for faster diagnostic solutions.” – Alec Ford, CEO at Karius
- “Investing in Karius addresses critical gaps in healthcare diagnostics… Precisely identifying pathogens allows for targeted treatment.” – Alex Morgan, Partner at Khosla Ventures
- “We’ve done extensive due diligence, and the value that Karius brings to patients and the healthcare system at large is abundantly clear.” – Isabelle De Cremoux, CEO and Managing Partner at Seventure Partners
SoHC's Take
Karius’ significant Series C funding is not just a financial boost but a pivotal step in revolutionizing how infectious diseases are diagnosed across the healthcare landscape. By expanding the accessibility and efficacy of the Karius Test®, the company addresses a vital need for speed and precision in diagnostics, essential for improving patient outcomes in critical conditions. With the backing of influential investors and a strong focus on technology-driven healthcare solutions, Karius is poised to make a substantial impact on global health diagnostics.
